INMUNE BIO INC. - COMMON STOCK

9.3000

13-February-25 16:45:00

15 minutes delayed

Stocks

+0.1700

+1.86%

Today's range

8.6600 - 9.4900

ISIN

N/A

Source

NASDAQ

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. to Join Russell 3000® Index

30 May 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

09 May 2024 16:05:36 By Nasdaq GlobeNewswire
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

07 May 2024 08:00:01 By Nasdaq GlobeNewswire
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

30 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

29 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

25 Apr 2024 09:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

23 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

22 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

08 Apr 2024 08:00:01 By Nasdaq GlobeNewswire
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

28 Mar 2024 16:01:53 By Nasdaq GlobeNewswire
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

26 Mar 2024 16:01:00 By Nasdaq GlobeNewswire
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

13 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

12 Feb 2024 09:00:00 By Nasdaq GlobeNewswire
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

06 Feb 2024 09:00:00 By Nasdaq GlobeNewswire
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

30 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

02 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

18 Dec 2023 16:01:00 By Nasdaq GlobeNewswire
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

29 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.